Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

BACKGROUND: Although patients with EGFR‐mutant non‐small‐cell lung cancer (NSCLC) benefit from treatment with EGFR‐tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Qi, Han, Qing, Gou, Song, Ze, Xie, Lin, Cao, Fei, Chen, Xiaoming, Fan, Weijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068442/
https://www.ncbi.nlm.nih.gov/pubmed/29924498
http://dx.doi.org/10.1111/1759-7714.12779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068442/
https://www.ncbi.nlm.nih.gov/pubmed/29924498
http://dx.doi.org/10.1111/1759-7714.12779

Ejemplares similares